| |
|
Mission
NexusPharma is dedicated to the discovery of novel therapeutics that modulate protein-protein interactions.
Novel drug candidates will be advanced into clinical development for the treatment of cancer through approaches
based on non-cytotoxic mechanisms.
Applying its patented technologies discovered at Fox Chase Cancer Center, NexusPharma has discovered
novel small-molecule protein-protein interaction inhibitors (PPII's) for a variety of biological targets.
As a co-founder of NexusPharma, Fox Chase Cancer Center supports the development of a physiological, cost-effective
platform for pre-clinical compound assessment along with other research activities at NexusPharma scheduled for the
coming years.
|
|
